ERBB2 and glioblastoma: On this basis, the CAR2BRAIN phase 1 multicenter German-wide dose-escalation clinical trial evaluates the safety and tolerability of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma (NCT03383978) [114].